References
1. Chuu, CP, Hiipakka, RA, Fukuchi, J, Kokontis, JM, and Liao, S. 2005. Androgen causes growth suppression and reversion of androgen-independent prostate cancer xenografts to an androgen-stimulated phenotype in athymic mice. Cancer Res 65(6): 2082-2084.
2. Denmeade, SR and Isaacs, JT. 2010. Bipolar androgen therapy: the rationale for rapid cycling of supraphysiologic androgen/ablation in men with castration resistant prostate cancer. Prostate 70(14): 1600-1607.
3. Denmeade, SR, Wang, H, Agarwal, N, et al. 2021. TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer. Journal of Clinical Oncology 39(12): 1371-1382.
4. Markowski, MC, Wang, H, Sullivan, R, et al. 2020. A Multicohort Open-label Phase II Trial of Bipolar Androgen Therapy in Men with Metastatic Castration-resistant Prostate Cancer (RESTORE): A Comparison of Post-abiraterone Versus Post-enzalutamide Cohorts. Eur Urol 79(5): 692-699.
5. Mohammad, OS, Nyquist, MD, Schweizer, MT, et al. 2017. Supraphysiologic Testosterone Therapy in the Treatment of Prostate Cancer: Models, Mechanisms and Questions. Cancers 9(12): 166.
6. Mori, K, Kimura, T, Ito, K, et al. 2018. Earlier use of androgen receptor-axis-targeted drugs may improve overall survival in patients with non-metastatic castration-resistant prostate cancer. Prostate 78(10): 766-772.
7. Moses, M, Koksal, U, Ledet, E, et al. 2020. Evaluation of the genomic alterations in the androgen receptor gene during treatment with high-dose testosterone for metastatic castrate-resistant prostate cancer. Oncotarget 11(1): 15-21.
8. Song, W, Soni, V, Soni, S, and Khera, M. 2017. Testosterone inhibits the growth of prostate cancer xenografts in nude mice. BMC Cancer 17(1): 635.
9. Tannock IF, dWR, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Théodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA. 2004. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351(15): 1502-1512.
10. Teply, BA, Wang, H, Luber, B, et al. 2017. Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study. Lancet Oncol 19(1): 76-86.
11. Yu P, DX, Cheng Y, Liu C, Chen Y, Liu W, Yin B, Wang X,Tao Z. 2017. Androgen-independent LNCaP cells are a subline of LNCaP cells with a more aggressive phenotype and androgen suppresses their growth by inducing cell cycle arrest at the G1 phase. Int J Mol Med 40:1426-1434.